Antioxidant

MPMBP binds to calcium phosphate in calcified tissues to reduce active oxygen and improve bone strength and orientation, addressing the limitations of high-dose bisphosphonic acid preparations by enabling effective treatment of metabolic and blood diseases at lower doses with reduced side effects.

WO2024247839A1PCT designated stage expired Publication Date: 2024-12-05KAZAMA JUNICHIRO
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018789
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-05-22
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Bisphosphonic acid preparations used for treating bone resorption conditions require continuous high-dose administration, leading to side effects such as osteonecrosis and renal failure, and their pharmacological effects are limited to osteoclasts, lacking systemic impact at lower concentrations.

Method used

A bisphosphonic acid compound, [4-(Methylthio)phenylthio]methanebisphosphonic acid (MPMBP), binds to calcium phosphate in calcified tissues, reducing active oxygen levels and exerting antioxidant effects, allowing for systemic medicinal effects at lower doses without affecting osteoclast function.

Benefits of technology

MPMBP reduces active oxygen in calcified tissues and blood, providing continuous systemic effects and improving bone strength and orientation, thereby treating metabolic bone diseases and blood diseases at lower doses with reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018789_05122024_PF_FP_ABST
    Figure JP2024018789_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention addresses the problem of providing a novel method for using, at a relatively low concentration, a bisphosphonic acid preparation previously intended to be used only at a high concentration. Provided is an antioxidant for binding with calcium phosphate and reducing the amount of active oxygen in calcified tissue, blood, interstitial fluid, or lymph. The antioxidant contains a compound, or a pharmaceutically acceptable salt thereof, represented by a formula (I).
Need to check novelty before this filing date? Find Prior Art

Description

antioxidants

[0001] The present invention relates to an antioxidant, a food, drink, and pharmaceutical composition containing the same, and a calcium phosphate binder.

[0002] Bisphosphonic acids (BPs), which have two phosphate groups attached to the central carbon atom, are known to inhibit bone resorption by inhibiting osteoclast function. To date, a wide variety of BPs, primarily those with various side chains attached to the carbon atom, have been developed and are widely used as drugs for various diseases associated with increased bone resorption, such as osteoporosis, hypercalcemia, Paget's disease, and tumor-induced bone destruction.

[0003] Bisphosphonic acids are broadly classified into two types depending on whether or not they contain a nitrogen atom in the side chain, and the elements contained in the side chain are halogen, nitrogen, sulfur, etc., and their structures vary widely, such as linear, cyclic, etc. Although there are subtle differences in the mechanism of action for their pharmacological effects due to these differences in side chain structure, all bisphosphonic acid preparations have in common the fact that they are first taken up by osteoclasts.

[0004] Thus, because it is necessary to allow each osteoclast to take up a sufficient amount of bisphosphonic acid, bisphosphonic acid preparations are required to be continuously administered at a high concentration. Furthermore, many bisphosphonic acid preparations have been problematic in that they cause serious side effects (osteonecrosis of the jaw, atypical femoral fracture, renal failure, etc.) when administered for a long period of time, although the incidence is low (Non-Patent Document 1).

[0005] [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP) has been developed as a bisphosphonic acid drug with reduced side effects (Patent Document 1). MPMBP has attracted attention as a compound that reduces side effects by suppressing the worsening of bacterial infection, which is thought to be one of the causes of osteonecrosis of the jaw, a side effect of bisphosphonic acid drugs, due to the antioxidant activity of its side chain.

[0006] WO 2010 / 026701

[0007] Journal of the Japanese Pharmacological Society, 2019, Vol. 153, No. 1, pp. 4-10

[0008] Although MPMBP was useful in reducing side effects, continuous administration at high concentrations was naturally required to obtain a sufficient bone resorption inhibitory effect.

[0009] An object of the present invention is to provide a new method for using bisphosphonic acid preparations at relatively low concentrations, which have previously only been envisaged for use at high concentrations.

[0010]

[0003] As a result of intensive research conducted by the present inventors to solve the above problems, it was found that bone strength is improved even when bisphosphonic acid preparations are administered at concentrations that do not affect osteoclast function. Furthermore, it was found that the pharmacological action of bisphosphonic acid preparations is observed in the blood, despite administration at such relatively low concentrations. The present invention is based on the novel finding that administration of a small amount of bisphosphonic acid preparation results in continuous systemic pharmacological effects starting from binding of the bisphosphonic acid preparation to calcified tissue, and provides the following:

[0011] [1] An antioxidant for binding to calcium phosphate and reducing the amount of active oxygen in calcified tissue, blood, tissue fluid, or lymph, the antioxidant comprising a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein R1 represents a hydrocarbon group or a hydrocarbon group having a substituent) [2] The antioxidant according to [1], wherein the calcified tissue is ectopic calcified tissue. [3] The antioxidant according to [2], wherein the ectopic calcified tissue is vascular tissue. [4] A food or drink comprising the antioxidant according to any one of [1] to [3]. [5] A pharmaceutical composition comprising the antioxidant according to any one of [1] to [3]. [6] The pharmaceutical composition according to [5], for preventing or treating a blood disease. [7] The pharmaceutical composition according to [6], wherein the blood disease is one or more diseases selected from the group consisting of blood clot formation, hyperlipidemia, uremia, diabetes, and hypertension. [8] A composition for preventing or treating a metabolic bone disease, comprising the antioxidant according to any one of [1] to [3] in an amount such that the weekly dose to a subject weighing 60 kg is 31 μmol or less. [9] The composition according to [8], wherein the metabolic bone disease is one or more diseases selected from the group consisting of osteoporosis, osteomalacia, rickets, and osteopetrosis.

[10] A calcium phosphate binder comprising a compound represented by the following formula (II) or a pharmaceutically acceptable salt thereof: (wherein R2 represents a substituted hydrocarbon group.)

[11] The calcium phosphate binder according to

[10] , wherein the substituted hydrocarbon group has a detectable label and / or a pharmacological action. This specification incorporates the disclosure of Japanese Patent Application No. 2023-086609, from which the present application claims priority.

[0012] The antioxidant of the present invention can reduce the amount of active oxygen in calcified tissue, blood, tissue fluid, or lymph.

[0013] The composition of the present invention can prevent or treat blood disorders and / or metabolic bone disorders.

[0014] The calcium phosphate binder of the present invention can bind to calcium phosphate and exert a desired effect.

[0015] Figure 1 shows the results of bone mineral density measurements in the femur. Figure 1A is a schematic diagram showing the sections of the femur from which the data shown in Figures 1B-E were taken. Figure 1B is a graph showing the results of bone mineral density measurements in the proximal region. In Figure 1A, vertical dashed lines indicate the boundaries of each section, and horizontal dashed lines indicate the central axis of the femur. In Figure 1B, "Cont" indicates the results for the control group, "Adenine Diet" indicates the results for the high-adenine diet group, "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In Figure 1B, ** indicates p<0.01. Figure 1 shows the results of bone mineral density measurements in the femur. Figure 1C is a graph showing the results of bone mineral density measurements in the proximal diaphysis. In the figure, "Cont" indicates the results for the control group, and "Adenine Diet" indicates the results for the high-adenine diet group. Of these, "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP group administered at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP group administered at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05. Figure 1 shows the results of bone mineral density measurements in the femur. Figure 1D is a graph showing the results of bone mineral density measurements in the distal diaphysis. In the figure, "Cont" indicates the results for the control group, and "Adenine Diet" indicates the results for the high-adenine diet group. Of these, "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP group administered at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP group administered at a dose of 1.2 mg / kg body weight. Figure 1 shows the results of bone mineral density measurements in the femur. Figure 1E is a graph showing the results of bone mineral density measurements in the distal region. In the figure, "Cont" indicates the results for the control group, "Adenine Diet" indicates the results for the high-adenine diet group, of which "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05. Figure 2 shows the results of storage modulus measurements in the femur.In the figure, "Cont" indicates the results for the control group, "Adenine Diet" indicates the results for the high-adenine diet group, "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight. * indicates p<0.05. Figure 3 shows the results of measuring apatite orientation in the femur. Figure 3A is a schematic diagram showing the sections of the femur from which the data shown in Figures 3B-E were taken. Figure 3B is a graph showing the results of measuring apatite orientation in the proximal region. In Figure 3A, the vertical dashed lines indicate the boundaries of each section, the horizontal dashed line indicates the central axis of the femur, and the black circles indicate the positions of the measurement points. In Figure 3B, "Cont" indicates the results for the control group, "Adenine Diet" indicates the results for the high-adenine diet group, "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In Figure 3B, * indicates p<0.05, and ** indicates p<0.01. Figure 3 shows the results of measuring apatite orientation in the femur. Figure 3C is a graph showing the results of measuring apatite orientation in the proximal diaphysis. In the figure, "Cont" indicates the results for the control group, "Adenine Diet" indicates the results for the high-adenine diet group, "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05, and ** indicates p<0.01. Figure 3 shows the results of measuring apatite orientation in the femur. Figure 3D is a graph showing the results of measuring apatite orientation in the distal diaphysis. In the figure, "Cont" indicates the results for the control group, "Adenine Diet" indicates the results for the high-adenine diet group, of which "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight.In the figures, * indicates p<0.05, and ** indicates p<0.01. Figure 3 shows the results of measuring apatite orientation in the femur. Figure 3E is a graph showing the results of measuring apatite orientation in the distal region. In the figures, "Cont" indicates the results for the control group, "Adenine Diet" indicates the results for the high-adenine diet group, "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figures, * indicates p<0.05, and ** indicates p<0.01. Figure 4 shows the results of measuring malondialdehyde levels in tibia samples. In the figure, "Cont" indicates the results for the control group, and "Adenine Diet" indicates the results for the high-adenine diet group. Of these, "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05. Figure 5 shows the results of measuring malondialdehyde levels in serum samples. In the figure, "Cont" indicates the results for the control group, and "Adenine Diet" indicates the results for the high-adenine diet group. Of these, "Veh" indicates the results for the vehicle-administered group, "MPMBP 0.6" indicates the results for the MPMBP-administered group at a dose of 0.6 mg / kg body weight, and "MPMBP 1.2" indicates the results for the MPMBP-administered group at a dose of 1.2 mg / kg body weight. In the figure, * indicates p<0.05.

[0016] 1. Antioxidant 1-1. Overview A first aspect of the present invention is an antioxidant. The antioxidant of the present invention comprises a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and reduces the amount of active oxygen in calcified tissue, blood, interstitial fluid, or lymph. The antioxidant of the present invention can be an active ingredient in foods, beverages, and pharmaceutical compositions.

[0017] 1-2. Definition "Antioxidants" (antioxidants or antioxidants) refer to substances that remove or eliminate active oxygen (superoxide anion, hydroxyl radical, hydrogen peroxide, singlet oxygen, etc.). Specifically, they include substances that can suppress harmful reactions involving active oxygen by reducing active oxygen and changing it into stable molecules. Many antioxidants are biosynthesized by animals and plants, and representative biologically derived antioxidants include vitamin C (ascorbic acid), vitamin E (tocopherol), coenzyme Q10, carotenoids, and flavonoids.

[0018] "Reactive oxygen" is a general term for highly reactive molecular species derived from oxygen molecules. In this specification, "reactive oxygen" refers to superoxide anion (O2 - ), superoxide anion radical (·O2 - ), peroxide ions (O2 2- ), hydroxyl radical (·OH), hydrogen peroxide (H2O2), singlet oxygen ( 1 O2) and ozone (O3).

[0019] "Calcium phosphate" is a compound consisting of calcium ions and phosphate ions (PO3 -4 ) or diphosphate ion (P2O4 -7 It is widely found in nature as a component of hard tissues such as bones and teeth of vertebrates.

[0020] "Blood" refers to a body fluid that fills the lumen of blood vessels. As used herein, "blood" includes whole blood, plasma, and serum. Any type of whole blood may be used, including venous blood, arterial blood, and umbilical cord blood.

[0021] "Lymph" refers to the bodily fluid that fills the lymphatic vessel lumen. It is mainly composed of plasma components, but when it passes through the lymphatic vessels, it is called lymph even if the same components are present in the blood.

[0022] "Tissue fluid" refers to the bodily fluid present between cells in tissues other than the lumen of blood vessels and lymphatic vessels. It is also called intercellular fluid or interstitial fluid.

[0023] The term "calcified tissue" refers to tissue that has hardened due to the deposition of calcium salts. Although it may refer to soft tissue that has hardened due to the deposition of calcium salts (ectopic calcified tissue in this specification), the term "calcified tissue" in this specification broadly includes tissue in which calcium salts have been deposited, including hard tissue and ectopic calcified tissue.

[0024] "Hard tissue" refers to a hard tissue that an organism has. In vertebrates, this generally includes bones, teeth, hair, nails, cartilage, etc. In particular, "hard tissue" in this specification refers to tissue in which calcium salts are deposited that is present in the body of a vertebrate under normal conditions. Hard tissue in this specification includes bones and teeth.

[0025] "Ectopic calcified tissue" refers to connective tissue other than bone tissue that has hardened due to the deposition of calcium salts. "Bone tissue" refers to tissue that is composed of osteoblasts, osteocytes, osteoclasts, and bone matrix and that constitutes bone mass.

[0026] "Blood disease" refers to a disease caused by an abnormality in the amount or function of blood cells, or an abnormality in blood coagulation factors or platelets, and is synonymous with hematological disease. Preferred blood diseases herein are diseases accompanied by an increase in the amount of reactive oxygen species in the blood.

[0027] "Metabolic bone disease" refers to a disease in which bone strength is reduced due to abnormalities in the metabolism of bone cells or bone tissue. Metabolic bone disease as used herein includes osteoporosis, osteomalacia, rickets, osteitis fibrosa cystica, Paget's disease of bone, osteopetrosis, etc.

[0028] "Significant" refers to statistical significance. Statistically significant refers to a significant difference between the measured values ​​of a test subject and a control value when the difference between the two is statistically processed. For example, the risk rate (significance level) of the obtained value is small, specifically, less than 5% (p<0.05), less than 1% (p<0.01), or less than 0.1% (p<0.001). The "p (value)" shown here indicates the probability that a test statistic will take that value by chance in a distribution based on the null hypothesis in a statistical test. Therefore, the smaller the "p", the lower the probability that the test statistic will take that value, meaning that the null hypothesis is more likely to be rejected. The statistical processing test method can be any known test method capable of determining the presence or absence of significance, and is not particularly limited. For example, Student's t-test, paired Student's t-test, Welch's t-test, Wilcoxon rank sum test, analysis of variance, Tukey post-hoc test, etc. can be used, but are not particularly limited.

[0029] 1-3. Constitution The antioxidant of the present invention contains a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an essential component, which will be explained in detail below.

[0030] (wherein R1 represents a hydrocarbon group or a hydrocarbon group having a substituent)

[0031] In the formula, the structure of R1 is not particularly limited as long as it is a hydrocarbon group or a hydrocarbon group having a substituent. The type of hydrocarbon group is not particularly limited. For example, an aliphatic hydrocarbon group, an aromatic hydrocarbon group, or a combination thereof can be used.

[0032] When an aliphatic hydrocarbon group is contained, it may be a saturated hydrocarbon or an unsaturated hydrocarbon. In this case, the structure of the aliphatic hydrocarbon group is not particularly limited. For example, it may have a linear, branched, or cyclic structure, or a structure of a combination thereof. When multiple aliphatic hydrocarbon groups are contained, they may have independent degrees of unsaturation and structures.

[0033] When an aromatic hydrocarbon group is contained, its structure is not particularly limited. For example, it may contain one aromatic ring such as a phenyl group, or may contain multiple aromatic rings such as a naphthyl group, a biphenyl group, an anthracenyl group, or a phenanthryl group, or may contain a cyclic structure other than an aromatic ring.

[0034] When the hydrocarbon group is unsaturated, the number of unsaturated bonds is not particularly limited. For example, it can be 0, 1 or more, 2 or more, 3 or more, or 4 or more. It can also be 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less. The type of unsaturated bond in the unsaturated hydrocarbon group is not particularly limited, and the unsaturated hydrocarbon group can contain any number of double bonds and any number of triple bonds.

[0035] When isomers exist, the type thereof is not particularly limited. For example, in the case of cis-trans isomers, each unsaturated bond may be either a cis or trans isomer, and in the case of optical isomers, each optical center may be either an R or S isomer.

[0036] The type of substituent is not particularly limited. Examples include substituents containing halogen, nitrogen, oxygen, sulfur, and phosphorus. Specific examples include carboxy groups, ketone groups, carbonyl groups, hydroxy groups, amino groups, imino groups, amide groups, hydrazide groups, imide groups, ester groups, alkyloxy groups, alkylsulfanyl groups, nitro groups, nitroso groups, selenium derivative groups, acid halide groups, nitrile groups, aldehyde groups, hydroxy groups, and hydroperoxy groups. Here, substituents in which a portion of the carbon skeleton is substituted with another element are also included. Therefore, heterocyclic functional groups are also included. The number of substituents is not particularly limited. For example, it can be 0, 1 or more, 2 or more, 3 or more, or 4 or more. It can also be 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less.

[0037] The number of unsaturated bonds contained in the R1 moiety is not particularly limited. For example, it can be 0, 1 or more, 2 or more, 3 or more, or 4 or more. It can also be 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less.

[0038] Specifically, the R1 moiety can be, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, or a derivative thereof. For example, a compound in which the R1 moiety is a methyl group is represented by formula (III) and is called [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP).

[0039]

[0040] The R1 moiety can have any function as long as it does not inhibit the antioxidant activity of the compound. In this case, the function is not particularly limited, but may be, for example, a moiety that can function as a detectable label or a moiety that has a pharmacological action. Specific examples of each will be described in detail in the fourth aspect.

[0041] The antioxidant of the present invention can contain a pharmaceutically acceptable salt of a compound represented by formula (I) as an essential component. The type of pharmaceutically acceptable salt of a compound represented by formula (I) is not particularly limited. For example, since the compound of formula (I) contains a phosphonic acid group, examples include base addition salts of the compound represented by formula (I). Base addition salts are formed with inorganic bases and / or organic bases. In this case, the type of inorganic base is not particularly limited. Examples of base addition salts with inorganic bases include ammonium salts, metal salts, and combinations thereof. Specific examples of metal salts include sodium salts, potassium salts, calcium salts, magnesium salts, iron salts, silver salts, zinc salts, copper salts, and combinations thereof. Furthermore, in the case of base addition salts with organic bases, the type of organic base is not particularly limited. Examples of organic bases include primary, secondary, and tertiary amines, substituted amines, cyclic amines, etc. Alternatively, a basic ion exchange resin can be used as the organic base.

[0042] Depending on the substitutions contained in the compound represented by formula (I), an acid addition salt of the compound represented by formula (I) can be used. The acid addition salt is formed with an inorganic acid and / or an organic acid. In this case, the type of inorganic acid is not particularly limited. Examples of acid addition salts with organic bases include hydrochlorides, hydrobromides, sulfates, nitrates, and phosphates. In addition, in the case of acid addition salts with organic acids, the type of organic acid is not particularly limited. Examples of organic acids include acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, and sulfosalicylic acid.

[0043] For example, the salt of the present invention may be a base addition salt of an inorganic base, such as a metal salt (e.g., an alkali metal salt such as a sodium salt). The salt may be an anhydrous or hydrated.

[0044] 1-4. Properties The antioxidant of the present invention binds to calcium phosphate in calcified tissues such as bone tissues by forming a chelate structure through coordination bonding of its bisphosphonate skeleton (—CH(PO(OH)2)2) to Ca.

[0045] Whether or not a compound binds to calcium phosphate can be confirmed by any method known in the art, but it can generally be considered that compounds having a bisphosphonate skeleton will bind to calcium phosphate.

[0046] The tissue containing calcium phosphate to which the antioxidant of the present invention binds is not particularly limited, but is preferably a calcified tissue. For example, the antioxidant binds to calcium phosphate in hard tissue such as bone tissue and / or ectopic calcified tissue. The calcified tissue in the ectopic calcified tissue is not particularly limited as long as it is a soft tissue, but is, for example, vascular tissue.

[0047] The antioxidant of the present invention binds to calcium phosphate via the bisphosphonate skeleton moiety and presents functional groups on its surface in the "side chain" that exert antioxidant activity, thereby reducing the amount of active oxygen in calcified tissue, or in blood, tissue fluid, or lymph.

[0048] The type of calcified tissue on which the antioxidant of the present invention exerts its antioxidant effect is not particularly limited, but examples include hard tissues such as bone tissue and / or ectopic calcified tissue. In this case, the calcified tissue in the ectopic calcified tissue is also not particularly limited as long as it is a soft tissue, but examples include vascular tissue. The tissue to which the antioxidant of the present invention binds and the tissue on which the antioxidant exerts its antioxidant effect may be the same or different, but typically include different tissues.

[0049] The reduction in the amount of reactive oxygen can be confirmed by any method. For example, the amount of reactive oxygen may be measured directly, or indirectly by measuring phenomena caused by reactive oxygen. Methods for directly measuring the amount of reactive oxygen include, for example, luminescence methods using luminescent probes, spin trapping methods, oxygen radical absorbance capacity (ROAC) measurement methods, singlet oxygen quenching capacity (SOAC) measurement methods, colorimetric methods using reducing agents, and combinations thereof. Methods for indirectly measuring the amount of reactive oxygen include, for example, measurement of nucleic acid damage, measurement of lipid peroxidation, measurement of protein oxidation or nitration, measurement of glycoxidation, measurement of antioxidants, or combinations thereof.

[0050] Specific indicators of nucleic acid damage include, for example, 8-OHG, 8-OHdG, abasic sites, double-strand breaks, BPDE adducts, or combinations thereof.

[0051] Specific indicators of lipid peroxidation include, for example, 8-OHG, 8-isoprostaglandin, acrolein, hexanoyl lysine, isoprostane, 4-hydroxynonenal, 4-hydroxyhexenal, malondialdehyde, crotonaldehyde, 7-ketocholesterol, lipid peroxides, oxidized LDL, or combinations thereof.

[0052] Specific indicators of protein oxidation or nitration include, for example, protein carbonylation, 3-nitrotyrosine, dityrosine, dibromotyrosine, advanced glycation end products (AGEs), protein peroxides, BPDE adducts, or combinations thereof.

[0053] Specific examples of glycosides include carboxymethyllysine, glycosylated albumin, menthosidine, methylglyoxal, 3-deoxyglucosone, and combinations thereof.

[0054] Specific examples of antioxidants include vitamin C, thiols, CoQ10 catalase, glutathione, glutathione reductase, glutathione peroxidase, myeloperoxidase, elastase, superoxide dismutase, paraoxonase, thioredoxin, thioredoxin reductase, selenoprotein, myostatin, or combinations thereof.

[0055] The method for measuring each target substance is not particularly limited, and any method known in the art can be used, including immunoassay, ELISA, colorimetric method, and various nucleic acid detection methods.

[0056] The amount of reactive oxygen species reduced by the use of the antioxidant of the present invention is not particularly limited. For example, the amount of reactive oxygen species may be reduced by 20% or more, 22% or more, 25% or more, 30% or more, 35% or more, 40% or more, 41% or more, 42% or more, 45% or more, 47% or more, 48% or more, 49% or more, 50% or more, 55% or more, 60% or more, 63% or more, or 64% or more compared to when the antioxidant of the present invention is not used. Alternatively, the amount of reactive oxygen species may be significantly reduced compared to when the antioxidant of the present invention is not used. Alternatively, the amount of reactive oxygen species may not be significantly increased when the antioxidant of the present invention is used compared to when the antioxidant is used.

[0057] 1-5. Effects The antioxidant of the present invention can exert its antioxidant effect at a dose that does not affect the function of osteoclasts.

[0058] The antioxidant of the present invention binds to calcified tissues, placing a side chain on the calcified tissue, and exerting a pharmacological effect on the tissues surrounding the calcified tissues through the action of the side chain, which is quite different from conventional bisphosphonic acid preparations, which are taken up by osteoclasts and thereby affect the osteoclasts themselves.

[0059] The antioxidant of the present invention is not only expected to be effective at low doses, but also has the potential to provide a continuous effect even with infrequent administration. Furthermore, because the antioxidant of the present invention reduces oxidative stress in the blood, it is expected to have a systemic effect starting from the binding of the antioxidant of the present invention to calcified tissues.

[0060] 2. Pharmaceutical Compositions 2-1. Overview A second aspect of the present invention is a pharmaceutical composition. The pharmaceutical composition of the present invention comprises an active ingredient as an essential component, and optionally comprises a solvent and a pharmaceutically acceptable carrier. The composition of the present invention can prevent or treat diseases or conditions such as blood disorders and / or metabolic bone disorders.

[0061] 2-2. Composition 2-2-1. Constituents The constituents of the pharmaceutical composition of the present invention will be described. The pharmaceutical composition of the present invention contains one or more active ingredients as essential components, and a solvent and / or carrier as optional components. Each component will be specifically described below.

[0062] (1) Active ingredient The pharmaceutical composition of the present invention contains the antioxidant described in the first aspect as an essential active ingredient, and may further contain one or more types of antioxidants, if necessary.

[0063] The constitution of the antioxidant is described in detail in the first aspect, and therefore a detailed description thereof will be omitted here. The pharmaceutical composition of the present invention may contain one or more types of antioxidants.

[0064] The content of the active ingredient contained in the pharmaceutical composition of the present invention is not particularly limited. Generally, the content varies depending on the type of active ingredient, the dosage form, and the type of solvent and carrier, which are other components described below. Therefore, it may be determined appropriately taking into account each condition. It is sufficient that an effective amount of the active ingredient is contained in a single dose of the pharmaceutical composition. However, if a large amount of the pharmaceutical composition needs to be administered to a subject to obtain the pharmacological effect of the active ingredient, it may be administered in several divided doses to reduce the burden on the subject. In this case, the total amount of the active ingredient is sufficient as long as it contains an effective amount.

[0065] An "effective amount" refers to the amount necessary for the active ingredient to function and to cause little or no harmful side effects to the subject to which it is applied. This effective amount may vary depending on various conditions, such as the subject's information, the route of application, and the number of applications. Therefore, when the pharmaceutical composition is used as a medicine, the content of the active ingredient is ultimately determined by the judgment of a doctor or pharmacist, etc.

[0066] The composition of this embodiment is effective even when the dose of the antioxidant administered is low. The dose of the antioxidant contained in the composition of the present invention and administered is not particularly limited, but for example, when converted to a weekly dose for a human subject weighing 60 kg, it can be 1 μmol or more, 2 μmol or more, 5 μmol or more, 7 μmol or more, 9 μmol or more, 10 μmol or more, 11 μmol or more, 12 μmol or more, 13 μmol or more, 13.5 μmol or more, 14 μmol or more, 14.5 μmol or more, 15 μmol or more, 15.5 μmol or more, 15.6 μmol or more, 15.7 μmol or more, It can be 15.8 μmol or more, 15.9 μmol or more, 16 μmol or more, 16.5 μmol or more, 17 μmol or more, 17.5 μmol or more, 18 μmol or more, 18.5 μmol or more, 19 μmol or more, 19.5 μmol or more, 20 μmol or more, 21 μmol or more, 24 μmol or more, 25 μmol or more, 26 μmol or more, 27 μmol or more, 28 μmol or more, 29 μmol or more, 30 μmol or more, 30.5 μmol or more, or 31 μmol or more. Furthermore, for example, when converted into a weekly dosage for a human subject weighing 60 kg, the dosage can be 31 μmol or less, 30.5 μmol or less, 30 μmol or less, 29 μmol or less, 28 μmol or less, 27 μmol or less, 26 μmol or less, 25 μmol or less, 24 μmol or less, 21 μmol or less, 20 μmol or less, 19.5 μmol or less, 19 μmol or less, 18.5 μmol or less, 18 μmol or less, 17.5 μmol or less, 17 μmol or less, 16.5 μmol or less, 16 μmol or less, 15.9 μmol or less, 15.8 μmol or less, or 15.7 μmol or less.

[0067] As used herein, the term "subject" refers to a target to which the antioxidant described in the first aspect or the pharmaceutical composition of this aspect is applied. Examples include cells (including cultured cells), tissues, organs, or individuals. When the subject is an individual, it may be any vertebrate, including humans, such as birds, reptiles, mammals, and primates. Examples of subjects other than humans include pets (dogs, cats, rabbits, etc.), racehorses, laboratory animals (mice, rats, guinea pigs, monkeys, etc.), and livestock (cows, horses, sheep, goats, pigs, chickens, ostriches, etc.). In the present invention, subjects may be healthy or suffering from a disease, and include, for example, individuals with or expected to have increased levels of reactive oxygen species.

[0068] As used herein, "subject information" refers to various information relating to the characteristics and condition of a subject. For example, when the subject is a human individual, information may include age, weight, sex, general health condition, presence or absence of disease, progression and severity of disease, drug sensitivity, presence or absence of concomitant medication, and resistance to treatment.

[0069] (2) Solvent The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable solvent as needed. "Pharmaceutically acceptable solvent" refers to a solvent commonly used in the pharmaceutical formulation field. Examples include water, an aqueous solution, or an organic solvent. Aqueous solutions include, for example, physiological saline, an isotonic solution containing glucose or other adjuvants, a phosphate buffer solution, and a sodium acetate buffer solution. Adjuvants include, for example, D-sorbitol, D-mannose, D-mannitol, sodium chloride, and other low-concentration nonionic surfactants, polyoxyethylene sorbitan fatty acid esters, etc. Organic solvents include ethanol.

[0070] (3) Carrier The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier as needed. The term "pharmaceutically acceptable carrier" refers to an additive commonly used in the pharmaceutical technology field. Examples include excipients, binders, disintegrants, fillers, emulsifiers, flow regulators, lubricants, human serum albumin, etc.

[0071] Excipients include, for example, sugars such as monosaccharides, disaccharides, cyclodextrins and polysaccharides, metallic salts, citric acid, tartaric acid, glycine, polyethylene glycol, Pluronic®, kaolin, silicic acid, or combinations thereof.

[0072] Examples of binders include starch paste using vegetable starch, pectin, xanthan gum, simple syrup, glucose solution, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, shellac, paraffin, polyvinylpyrrolidone, and combinations thereof.

[0073] Disintegrants include, for example, the above-mentioned starches, lactose, carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, laminaran powder, sodium bicarbonate, calcium carbonate, alginic acid or sodium alginate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, or salts thereof.

[0074] Examples of fillers include petrolatum, the aforementioned sugars and / or calcium phosphate.

[0075] Examples of emulsifiers include surfactants (for example, polyethylene glycol, poloxamer, glyceryl acetate, isostearamide, sorbitan fatty acid ester, glycerin fatty acid ester, sucrose fatty acid ester, and propylene glycol fatty acid ester).

[0076] Examples of flow regulators and lubricants include silicates, talc, stearates or polyethylene glycol.

[0077] Examples of pH adjusters include alkaline agents such as sodium hydroxide and potassium hydroxide, and acid agents such as citric acid, sodium citrate, glycolic acid, and ascorbic acid.

[0078] In addition to the above, if necessary, the composition may appropriately contain solubilizers, suspending agents, diluents, dispersing agents, surfactants, soothing agents, stabilizers, absorption promoters, bulking agents, moisturizing agents, humectants, wetting agents, adsorbents, flavoring agents, disintegration inhibitors, coating agents, colorants, preservatives, antiseptics, antioxidants, fragrances, flavoring agents, sweeteners, buffers, isotonic agents, and the like that are commonly used in pharmaceutical compositions and the like.

[0079] The carrier is used to avoid or suppress the decomposition of the active ingredient by enzymes and the like in the subject's body, as well as to facilitate formulation and administration methods and maintain the dosage form and medicinal efficacy, and may be used appropriately as needed.

[0080] (4) Drug Delivery System Particles (DDS Particles) The pharmaceutical compositions of the present invention may contain DDS particles, if necessary. DDS particles are particles that encapsulate active ingredients or other carriers, deliver their contents, particularly the active ingredients, to target sites without degradation, and can control the time and quantity of drug distribution in vivo. Because the active ingredients of the pharmaceutical compositions of the present invention are peptides or nucleic acids, the use of DDS particles is also suitable for protecting them from degradation by proteases and nucleases in vivo after administration. Any type of DDS particle may be used. Examples include liposomes, polymeric micelles, and virus particles.

[0081] The dosage form of the pharmaceutical composition of the present invention is not particularly limited as long as it is in a form that allows the active ingredient to be delivered to the target site in the body of the subject without being inactivated.

[0082] The specific dosage form varies depending on the application method, which will be described later. The application method can be roughly divided into parenteral administration and oral administration, so a dosage form suitable for each administration method may be used.

[0083] For example, if the administration method is parenteral administration, a preferred dosage form is a liquid that can be administered directly to the target site or systemically via the circulatory system. A preferred example of a liquid is an injection. An injection can be formulated by appropriately combining a solvent with the above-mentioned excipients, emulsifiers, suspending agents, surfactants, stabilizers, pH adjusters, etc., and mixing them in a unit dose form required for generally accepted pharmaceutical practice.

[0084] When the administration method is oral administration, preferred dosage forms include solids (including tablets, capsules, drops, and lozenges), granules, powders, powders, and liquids (including oral solutions, emulsions, and syrups). If a solid is used, it can be made into a dosage form coated with a coating known in the art, such as sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, double tablets, and multi-layer tablets, as needed.

[0085] The specific shape and size of each of the above dosage forms are not particularly limited as long as they are within the range of dosage forms known in the art. The pharmaceutical composition of the present invention may be formulated according to a conventional method in the art.

[0086] 2-3. Application Method The pharmaceutical composition of the present invention may be administered orally or parenterally. Generally, oral administration is systemic administration, but parenteral administration can be further divided into systemic administration and local administration. Local administration includes, for example, intramuscular administration, subcutaneous administration, tissue administration, and organ administration, and systemic parenteral administration includes intracirculatory administration, for example, intravenous administration (intravenous injection), intraarterial administration, and intralymphatic administration. When the pharmaceutical composition of the present invention is administered locally, it may be administered directly to the liver by injection, etc. When it is administered systemically, it may be administered into the circulatory system, for example, by intravenous injection. The dosage may be any amount effective for the active ingredient to be effective. The effective amount is selected appropriately depending on the subject information, as described above.

[0087] The pharmaceutical composition of the present invention can also be used in combination with one or more other known antioxidants, such as vitamin C (ascorbic acid), vitamin E (tocopherol), coenzyme Q10, carotenoids, flavonoids, or combinations thereof.

[0088] 2-4. Target Diseases or Conditions The composition of the present invention can prevent or treat diseases or conditions known to be associated with an increase in the amount of reactive oxygen species.

[0089] As used herein, the term "prevention" refers to preventing the onset of a disease (here, for example, osteoporosis, etc.) before it occurs.

[0090] As used herein, the term "treatment" refers to the cure or amelioration of a disease. Here, "amelioration" refers to the alleviation or elimination of symptoms associated with the disease and / or the prevention or suppression of progression.

[0091] The compositions of the present invention are particularly useful for prevention because they can exert a continuous systemic effect at low doses. In this case, the compositions of the present invention are administered to healthy individuals or individuals expected to have an increased amount of reactive oxygen species. Individuals expected to have an increased amount of reactive oxygen species include those who do not have symptoms but have factors that cause an increase in the amount of reactive oxygen species. Such factors include any factors that have been shown to increase the amount of reactive oxygen species, including, but not limited to, lifestyle habits, genetic factors, and psychological factors.

[0092] The disease or condition to be prevented or treated by the composition of the present invention is not particularly limited as long as it is a disease or condition known to increase the amount of reactive oxygen species, and examples thereof include blood diseases, metabolic bone diseases, lifestyle-related diseases, inflammatory diseases, autoimmune diseases, degenerative diseases (Alzheimer's disease, amyotrophic lateral sclerosis, Lou Gehrig's disease, etc.), cancer, etc.

[0093] Specific examples of blood diseases include blood clot formation, hyperlipidemia, uremia, diabetes, hypertension, fatty liver disease, alcoholic liver disease, kidney disease (e.g., renal failure such as chronic renal failure), diabetic kidney disease, polycystic kidney disease, heart failure, leukocytosis, neutropenia and leukocytosis, myeloid and lymphocytic leukemia, myeloproliferative neoplasms, myelodysplastic syndrome, aplastic anemia, paroxysmal nocturnal hemoglobinuria, malignant lymphoma, and multiple myeloma.

[0094] Specific metabolic bone diseases or conditions include, for example, osteoporosis, osteomalacia, rickets, osteopetrosis, hypogonadism, androgen suppression, vitamin D deficiency, secondary hyperparathyroidism, osteochondritis disease, osteochondroma, osteitis deformans, osteoarthritis, fibrous dysplasia, osteitis fibrosa cystica, symphysis pubis, sclerosing osteitis, osteogenesis imperfecta, osteomyelitis, osteopenia, osteonecrosis, bone atrophy, osteophytes, Paget's disease, hypercalcemia, neoplastic destruction of bone, fractures, bone loss, cancer-related bone resorption diseases, osteolysis, osteoarthritis, rheumatoid arthritis, nutritional deficiencies, and anorexia nervosa.

[0095] When the composition of the present invention is used to treat metabolic bone diseases, it improves apatite orientation in bone and / or bone mechanical properties (e.g., elastic modulus such as storage modulus). Preferably, apatite orientation is improved without changing bone density or affecting the function of osteoclasts or osteoblasts.

[0096] In this specification, the term "apatite orientation" refers to the orientation of the crystal structure composed of collagen and hydroxyapatite in the c-axis direction (thickness direction).

[0097] The composition of the present invention can be used to treat metabolic bone diseases accompanied by a decrease in apatite orientation in bones. The degree of decrease is not particularly limited, and the composition can be used to treat metabolic bone diseases in which apatite orientation is decreased to 90% or less, 85% or less, 84.5% or less, 84% or less, 83% or less, 82% or less, 81% or less, 80% or less, 79% or less, 78% or less, 77% or less, 76% or less, 75% or less, 74% or less, 73% or less, 72% or less, 71% or less, or 70% or less compared to healthy individuals of the same species.

[0098] The composition of the present invention can be used to treat metabolic bone diseases accompanied by a decrease in bone elastic modulus, particularly storage modulus. The degree of decrease is not particularly limited, and examples of metabolic bone diseases that can be treated include those in which the storage modulus is reduced to 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 54% or less, or 53.5% or less compared to healthy individuals of the same species. The storage modulus can be measured as Young's modulus.

[0099] The compositions of the present invention can be used to treat metabolic bone diseases both associated with and without a decrease in bone density. When a decrease in bone density is associated with the disease, the degree of decrease is not particularly limited. Examples include metabolic bone diseases in which bone density is reduced to less than 90% compared to healthy individuals of the same species. In cases where bone density is not reduced, the bone density may be at least 90% of that of healthy individuals of the same species, including diseases exhibiting bone density of at least 90.5%, at least 91%, at least 91.4%, at least 91.5%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 97.5%, at least 97.8%, at least 97.9%, at least 98%, and at least 99%. Bone density can be measured using known methods, such as DXA, ultrasound, MD, and X-ray. As used herein, the term "inflammatory disease" refers to a disease that involves persistent or transient inflammation, the symptoms of which can be improved by reducing the inflammation. Inflammatory diseases as used herein include both chronic inflammatory diseases and acute inflammatory diseases.

[0100] Specific examples of inflammatory diseases include allergic inflammatory diseases such as hay fever and delayed-type allergies; neuroinflammatory diseases such as diabetic neuropathy, dementia (Alzheimer's disease, etc.), and multiple sclerosis; cancers caused by chronic inflammation such as colon cancer, lung cancer, bladder cancer, skin cancer, esophageal cancer, and liver cancer; inflammatory diseases involving macrophages such as hepatitis (alcoholic hepatitis, non-alcoholic hepatitis, etc.), asthma, systemic lupus erythematosus, Crohn's disease, and arthritis (chronic rheumatoid arthritis, etc.); and other inflammatory diseases such as arteriosclerosis, gastric ulcer, nephritis (glomerulonephritis, IgA nephropathy, diabetic nephropathy, etc.), periodontal disease (gingivitis, peridontitis, etc.), damage caused by kidney transplantation, acute myocardial infarction, diabetes, reflux esophagitis, cholangitis, celiac disease, vasculitis, and atherosclerosis.

[0101] The target disease or condition may be, for example, a disease associated with ectopic calcification. Specific examples include vascular calcification (e.g., vascular calcification in dialysis patients, arteriosclerosis patients, etc.), calciphylaxis, diabetic vasculopathy, soft tissue calcification, ectopic ossification, rheumatism, osteoarthritis, fibrodysplasia ossificans progressiva, cancer, cancer metastasis, hypercalcemia, scleroderma, dermatomyositis, calcific tendonitis, calcific bursitis, focal calcification, generalized calcification, ossification of the posterior longitudinal ligament of the cervical spine, ossification of the spinal ligaments, hyperparathyroidism, vitamin D metabolic disorders, and vitamin D insufficiency. Examples of adverse reactions include poisons, arteriosclerosis (e.g., Mönckeberg arteriosclerosis), atherosclerosis, arteriosclerosis, hypertensive arteriosclerosis, Mönckeberg arteriosclerosis, heart valve stenosis, blood clot formation, uremia, diabetes, hypertension, Werner's syndrome, pseudoxanthoma elasticum, angina pectoris, myocardial infarction, myocardial damage, heart failure, cardiac conduction disorder, cerebral infarction, metastatic calcification, tartar formation, periodontal disease, bone and joint pain, bone deformity, fractures, muscle pain, wounds, inflammation, ischemic skin ulcers, urinary tract stones, kidney stones, renal failure, and chronic renal failure.

[0102] 3. Foods and Drinks 3-1. Overview A third aspect of the present invention is a food and drink. The food and drink of the present invention contains the antioxidant of the first aspect as an active ingredient. The food and drink of the present invention can exert antioxidant effects in calcified tissue, blood, tissue fluid, or lymph.

[0103] 3-2. Constitution The food and drink of the present invention comprises the antioxidant of Aspect 1. In this specification, the term "food and drink" is a general term that refers to beverages, foods, and feeds.

[0104] Examples of beverages include water (including purified water, mineral water, and deep sea water), tea drinks (including green tea, oolong tea, and black tea), coffee, coffee drinks, milk (including raw milk and processed milk), dairy drinks, lactic acid bacteria drinks, juice, soft drinks (including carbonated drinks, fruit juice drinks, powdered drinks, and sports drinks), jelly drinks, cocoa drinks, brewed alcohol (including beer, sake, yellow wine, wine, and cider), distilled alcohol (including whiskey, brandy, vodka, rum, tequila, shochu, white liquor, and gin), and mixed alcohol (including liqueur, plum wine, and vermouth).

[0105] The food includes general foods (especially processed foods) and foods for specified health uses. Examples of processed foods include bread, cooked rice, noodles, pasta, mayonnaise, shortening, custard cream, dressings, milk, yogurt, soup, miso soup, tofu, spreads (butter, jam, furikake, margarine, etc.), sauces, soy sauce, oil, and sweets (e.g., cookies, chocolate, candy, cake, ice cream, chewing gum), etc.

[0106] Examples of feed include feed for farmed fish and shellfish, feed for livestock, feed for ornamental animals, and pet food.

[0107] The antioxidant according to the first aspect is added to the food or drink of the present invention during or after production. The method for producing the food or drink of this aspect is not particularly limited. For example, the food or drink may be produced according to a conventional method by blending other food ingredients, various nutrients, various vitamins, minerals, amino acids, various oils and fats, and various additives (e.g., taste components, sweeteners, acidulants such as organic acids, surfactants, pH adjusters, stabilizers, antioxidants, colorants, flavors), etc., used in the food or drink production process. Alternatively, the food of the present invention can be produced by adding the antioxidant according to the first aspect to the food or drink after production.

[0108] The content of the antioxidant of the first aspect in the food or drink varies depending on the form and purpose of the food or drink. For example, the content can be set so that the food or drink is ingested at the dose exemplified in relation to the effective amount in the second aspect.

[0109] The food and drink of the present invention may contain a pharmaceutically or food hygienically acceptable solvent and / or carrier, if necessary.

[0110] Examples of pharmaceutically or food-hygienically acceptable solvents include water, or other pharmaceutically or food-hygienically acceptable solvents, such as aqueous solutions, oils, or organic solvents. As aqueous solutions and organic solvents, those mentioned above as pharmaceutically acceptable solvents can be used. Examples of food-hygienically acceptable oils include vegetable oils such as wheat germ oil, apricot oil, olive oil, camellia oil, evening primrose oil, aloe vera oil, rapeseed oil, palm oil, cottonseed oil, soybean oil, corn oil, safflower oil, sesame oil, linseed oil, and castor oil.

[0111] The food and drink of the present invention may contain a pharmaceutically or hygienically acceptable carrier as needed. Examples of the carrier include excipients, binders, fillers, emulsifiers, pH adjusters, hardening regulators, preservatives, and flow additive adjusters. In addition to the above, solubilizers, diluents, dispersants, stabilizers, humectants, preservatives, and tonicity adjusters may also be included as needed. Specific examples of the carrier include the various carriers listed above as pharmaceutically acceptable carriers.

[0112] The dosage form of the food or drink of the present invention is not particularly limited, and may be, for example, granules, powder, paste, gel, liquid, suspension, etc.

[0113] 4. Calcium phosphate binder 4-1. Overview A fourth aspect of the present invention is a calcium phosphate binder. The calcium phosphate binder of this aspect contains a compound represented by formula (II) or a pharmaceutically acceptable salt thereof as an active ingredient. The calcium phosphate binder of this aspect can deliver a desired substance to a site where calcium phosphate is present.

[0114] 4-2. Constitution The calcium phosphate binder of the present invention contains the compound represented by formula (II) or a pharmaceutically acceptable salt thereof as an essential component.

[0115] (wherein R2 represents a hydrocarbon group having a substituent.)

[0116] The hydrocarbon group and substituents, and the pharmaceutically acceptable salts are basically the same as those described in the first embodiment, so only the differences from the first embodiment will be explained here.

[0117] The R2 moiety in formula (II) may be a hydrocarbon group having a substituent, which has a detectable label and / or a pharmacological activity.

[0118] As used herein, the term "detectable label" refers to a substance that emits a signal that allows its presence to be detected. The type of label is not particularly limited. Examples include luminescent labels that emit light under specific conditions, such as fluorescent molecules and chemiluminescent substances, sound-emitting labels that emit sound waves, such as photoacoustic probes, and radioactive labels.

[0119] Specific examples of fluorescent molecules include fluorescent proteins, fluorescein and its derivatives, pyrene and its derivatives, quantum dots, etc. Chemiluminescent substances include enzymes such as peroxidase (HRP) and alkaline phosphatase (ALP). Radioactive labeling substances include, for example, 14 C. 3 H, 125 Examples of suitable photoacoustic probes include reagents containing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 112, 113, 114, 115, 120, 121, 122, 123, 124, 125, 130, 131, 132, 133, 134, 135, 140, 141, 142, 143,

[0120] "Pharmacological action" refers to an effect that brings about quantitative and / or qualitative changes in biomolecules such as proteins, DNA, and RNA. As a result of physiological effects, for example, changes occur in the functions and properties of living organisms, organs, tissues, cells, etc. There are no particular limitations on the targets of changes due to physiological activity. For example, when the calcium phosphate binder of the present invention contains a hydrocarbon group with a substituent having a pharmacological action, changes occur in biological functions such as metabolism, growth, reproduction, homeostasis, mental activity, and biodefense.

[0121] The specific pharmacological action is not particularly limited, and examples thereof include antioxidant action, anti-inflammatory action, blood circulation promoting action, blood sugar lowering action, antihypertensive action, fibrin formation inhibitory action, platelet aggregation inhibitory action, antibacterial action, antifungal action, tumor suppressive action, and cardiovascular protective action.

[0122] For example, existing bisphosphonic acid compounds or derivatives thereof can be used as the calcium phosphate binder of the present invention, specifically, for example, etidronate, clodronate, pamidronate, alendronate, risedronate, minodronate, ibandronate, incadronate, zoledronate, tiludronate, and the compounds of formula (I) (e.g., [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP)).

[0123] Example 1: Analysis of the effect of low concentrations of [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP) on bone (Objective) To examine the effect of low concentrations of [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP) on bone in rats, which are insufficient to regulate osteoclasts.

[0124] (Method) 1. Rat model Because it is known that bone metabolic abnormalities occur in chronic kidney disease, a chronic kidney disease model was used as a model of metabolic bone disease. Rats fed a high-adenine diet were used as the chronic kidney disease model. Eight-week-old wild-type male Sprague-Dawley rats obtained from Japan SLC were used.

[0125] After one week of breeding, the rats were divided into four groups of six (week 0). The control group continued to receive regular chow, while the other three groups continued to receive a high-adenine diet (Sigma-Aldrich) for seven weeks.

[0126] Starting from the third week, rats in each group received weekly intraperitoneal injections of vehicle or [4-(methylthio)phenylthio]methanebisphosphonic acid (MPMBP). Physiological saline was used as the vehicle. The MPMBP-treated groups received injections of MPMBP at two concentrations: 0.6 mg / kg body weight and 1.2 mg / kg body weight. MPMBP was provided by Showa University.

[0127] At week 7, 72 hours after administration of vehicle or MPMBP, rats in each group were sacrificed and subjected to subsequent analysis.

[0128] 2. Collection of bone samples Right femurs were collected from the sacrificed rats of each group and fixed in 70% ethanol.

[0129] 3. Bone mineral density measurement Bone mineral density (BMD) of the fixed femur was measured using Dual Energy X-ray Absorptiometry (DEXA) with a DCS-600-EX-III R (ALOKA). The femur was divided into four equal sections (between the vertical dashed lines in Fig. 1A) along the longitudinal axis (horizontal dashed line in Fig. 1A). BMD was measured for each section, starting from the femoral head, as follows: proximal, proximal diaphyseal, distal diaphyseal, and distal.

[0130] 4. Measurement of bone mechanical properties Young's modulus, which is the storage modulus, was measured in the combined proximal and distal diaphyseal sections of the fixed femur using an R-AXIS BQ (Rigaku Corporation).

[0131] 5. Trabecular Bone Morphometry Fixed femurs were embedded in methyl methacrylate resin (Fujifilm Wako Pure Chemical Industries, Ltd.) and then sectioned in the coronal plane (5 μm thick) using RM2255 (LEICA). The distal end of each section was stained with Villanueva Osteochrome Bone Stain (Polysciences). Trabecular bone morphometry was performed using OsteoMeasure (Shoshin EM) while observing the stained sections under an optical microscope (Nikon). Parameters measured included unit bone mass, trabecular bone width, formation surface, resting surface, resorption surface, osteoblast surface, bone formation rate, and mineralization rate.

[0132] 6. Statistical Analysis Statistical analysis was performed using SPSS by t-test, with p<0.05 used as the significance level.

[0133] (Results) The results are shown in Table 1 and Figures 1 and 2. Table 1 shows the results of trabecular bone morphometry.

[0134]

[0135] No significant differences were observed between the control and high-adenine diet groups in bone structure indices (bone mass, trabecular thickness, trabecular number, and trabecular spacing). Similarly, no significant differences were observed between the control and high-adenine diet groups in osteoblast-related indices (osteoblast surface, osteoid surface). Osteoclast-related indices (osteoclast number, erosion surface) were significantly higher in the high-adenine diet group compared with the control group. MPMBP administration had no effect on these indices. This was expected, likely due to the low concentration of MPMBP administered. Meanwhile, although the bone mineralization lag time was significantly higher in the high-adenine diet group compared with the control group, there was no significant difference between the MPMBP-administered group and the control group. These results suggest that low concentrations of MPMBP normalize bone formation without the previously thought mediation of osteoclast function.

[0136] The lack of effect of MPMBP at this concentration on bone structure was also supported by the results of bone mineral density measurements. As shown in Figure 1B-E, bone mineral density was generally reduced in the high-adenine diet group compared to the control group (Cont). However, MPMBP administration had no effect on these indices.

[0137] On the other hand, as shown in Figure 2, although bone mechanical properties of the femoral shaft were generally decreased in the high-adenine diet group (Adenine Diet) compared with the control group (Cont), MPMBP administration significantly improved them in a concentration-dependent manner. This result is consistent with the results of interfacial bone morphometry, which showed that bone formation was normalized without modulating osteoclast function.

[0138] Example 2 Analysis of the Cause of the Effects of Low Concentrations of MPMBP on Bone (Objective) To investigate the cause of the effects on bone of MPMBP at concentrations insufficient for regulating osteoclasts.

[0139] (Method) 1. Rat Model The rat model used in Example 1 was used.

[0140] 2. Apatite Orientation Measurement The c-axis orientation of apatite crystals in the proximal, proximal diaphyseal, distal diaphyseal, and distal center portions (black circles in Figure 3A) of the femur fixed in Example 1 was measured using R-AXIS BQ (Rigaku Corporation). The measurement parameters were as follows: collimator diameter: 300 μm; X-ray irradiation time: 180 sec.

[0141] 3. Sample Collection Right tibia samples and serum samples were collected from the sacrificed rats in each group. Tibia samples were prepared as follows: after removal of the tibia, the bone marrow was flushed out with phosphate-buffered saline, flash-frozen in liquid nitrogen, and pulverized. After pulverization, the bone fragments were decalcified in 0.5 M EDTA / Tris buffer (pH 7.4) for 96 hours. The decalcified bone fragments were reduced in NaBH4 / phosphate solution and used as tibia samples.

[0142] The weight of the tibia sample was measured as the bone tissue mass. Serum samples were prepared by centrifuging the collected blood at 2000 G for 20 minutes and recovering the supernatant.

[0143] The amount of malondialdehyde, a lipid peroxidation product, was measured in the obtained tibia and serum samples using a malondialdehyde measurement kit (Northwest Life Science Specialties LLC). The amount of malondialdehyde in the tibia samples was standardized by the mass of bone tissue, and the amount of malondialdehyde in the serum samples was standardized by the volume of the serum sample.

[0144] (Results) The results are shown in Figures 3 to 5. As shown in Figures 3B to 3E, apatite orientation was significantly reduced in the high-adenine diet group (Adenine Diet) compared to the control group (Cont), but the values ​​improved in an MPMBP dose-dependent manner. This suggests that MPMBP promotes the reorganization of crystalline structure in bone, improving apatite orientation and leading to improved bone mechanical properties.

[0145] To further clarify the cause, we measured the amount of malondialdehyde (a lipid peroxidation product) in bone. The results showed that the oxidative stress increased with the high-adenine diet was reduced by MPMBP administration (Figure 4). Furthermore, this effect was also observed in the blood, where it showed the same changes as serum oxidative stress (Figure 5). Furthermore, blood indicators showed no effect of MPMBP on renal function (data not shown).

[0146] These findings suggest that MPMBP reduces oxidative stress in the blood and bone, creating an environment conducive to the reorganization of bone crystal structure. Furthermore, the effects of MPMBP on bone are also evident in the blood, suggesting that MPMBP may exert an antioxidant effect on the bone surface. All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.

Claims

1. An antioxidant for binding to calcium phosphate and reducing the amount of active oxygen in calcified tissue, blood, tissue fluid, or lymph, the antioxidant comprising a compound represented by the following formula (I) or a pharma- ceutical acceptable salt thereof: (wherein R1 represents a hydrocarbon group or a hydrocarbon group having a substituent).

2. The antioxidant according to claim 1, wherein the calcified tissue is ectopic calcified tissue.

3. The antioxidant according to claim 2, wherein the ectopic calcified tissue is vascular tissue.

4. A food or drink comprising the antioxidant according to any one of claims 1 to 3.

5. A pharmaceutical composition comprising the antioxidant according to any one of claims 1 to 3.

6. The pharmaceutical composition according to claim 5 for preventing or treating a blood disorder.

7. The pharmaceutical composition according to claim 6, wherein the blood disease is one or more diseases selected from the group consisting of blood clot formation, hyperlipidemia, uremia, diabetes and hypertension.

8. A composition for preventing or treating a metabolic bone disease, comprising an antioxidant according to any one of claims 1 to 3 in an amount sufficient to provide a weekly dose of 31 μmol or less to a subject weighing 60 kg.

9. The composition of claim 8, wherein the metabolic bone disease is one or more diseases selected from the group consisting of osteoporosis, osteomalacia, rickets and osteopetrosis.

10. A calcium phosphate binder comprising a compound represented by the following formula (II) or a pharma- ceutically acceptable salt thereof: (In the formula, R2 represents a hydrocarbon group having a substituent.) 11. The calcium phosphate binder according to claim 10, wherein the hydrocarbon group having the substituent has a detectable label and / or a pharmacological action.

Citation Information

Patent Citations

  • Rear bumper structure made of resin

    JP1996026048A

  • Osteogenesis promoter comprising [4-(methylthio)phenylthio]methanebisphosphonic acid or pharmaceutically acceptable salt thereof as active ingredient

    WO2010026701A1